Research Events

29 Mar 2019

Organizers: IRB Barcelona
Date: Friday 29th March, 12.00h
Place: AUDITORIUM, Parc Cientific de Barcelona

Host: Patrick Aloy, PhD - IRB Barcelona

Abstract

2 Apr 2019 - 11 Apr 2019

Organizer: IRB Barcelona 

Date:  April 2-4-10-11, 09:30-12:00h
Place: Room Felix Serratosa, Parc Científic de Barcelona, Spain

 

4 Apr 2019

Organizers: IRB Barcelona
Date: Thursday 4th April, 15.00h
Place: Felix Serratosa Hall

Host: Manuel Serrano, Ph.D. -  IRB Barcelona

 

Plenary Seminar

5 Apr 2019

Organizers: IRB Barcelona
Date: Friday 5th April, 12.00h
Place: AUDITORIUM, Parc Cientific de Barcelona

Host: Xavier Salvatella, Ph.D.,  IRB Barcelona

 

Plenary Seminar

8 Apr 2019 - 10 Apr 2019

Cancer is a multi-hit process involving mutations in oncogenes and tumour suppressors. It is altered by its environment including interactions between the tumour cells and the surrounding normal tissue, immune response, and whole body metabolism. As such, cancer studies benefit from whole animal platforms. The fruit fly Drosophila is an excellent, genetically-tractable system for modelling the development of cancer due to the conservation of cell signalling, proliferation, and survival networks between fly and human.

16 Apr 2019

Date: Tuesday 16  and Thursday 18 April  2019
Time: 14:00  – 18:00
Place: Room 1 Tower I, PCB Barcelona

 

16 Apr 2019

Date: Tuesday, 16 and 18 April, 2019
Time: 09:00  – 13:00
Place: Room 1, Tower I, PCB Barcelona

 

31 May 2019

Organizers: IRB Barcelona
Date: Friday 31 May, 12.00h
Place: Felix Serratosa Hall, Parc Cientific de Barcelona

Host: Ángel R. Nebreda, PhD - IRB Barcelona

Abstract

14 Jun 2019

Organizers: IRB Barcelona
Date: Friday 14 June, 12.00h
Place: Felix Serratosa Hall, Parc Cientific de Barcelona

Host: Cayetano González, PhD - IRB Barcelona

Abstract

18 Nov 2019 - 20 Nov 2019

Stimulation of the immune system by blocking immunosuppressive checkpoints has shown spectacular impact in cancer therapy. There is increasing evidence that immunotherapy might elicit similar outcomes in non-oncological settings. This is the case, for example, of neurodegenerative disorders where blockade of immune checkpoints has beneficial effects.  More generally, aging is associated with a progressive unbalance in the composition and activity of the different components of the immune system.